Developmental Funds
Johns Hopkins University, Baltimore MD
Investigators
Linked publications & trials
Abstract
During the current project period, Developmental Funds have been essential to maintain and extend the reach and vitality of the scientific Programs in the Sidney Kimmel Comprehensive Cancer Center (SKCCC). Specific aims of the SKCCC Developmental Funds are: (1) to recruit cancer researchers in the strategic areas of need, and (2) to support staff investigators who are critical to the activities of the SKCCC. Use of these funds is closely tied to the SKCCC strategic plan, Innovation for Impact 2025. The funds have been used to build scientific strength in a number of Research Programs, by recruiting and supporting new laboratory, translational, and clinical investigators to populate the SKCCC Research Programs. During the current project period, 16 new investigators were recruited using $250,000 per year from Developmental Funds, leading to 51 new externally funded grants ($6.04 million annual direct costs representing a return-on-investment of 24 to 1). Currently, another 12 grants are pending, representing an additional $3.1 million in annual direct costs. A total of 128 peer-reviewed articles were published by the cohort of new investigators. Developmental Funds for Shared Resources (SRs) were invested in the Translational Research Central Services SR, now a fully established SR in this renewal application. In addition, the CCSG Developmental Funds were supplemented via an institutional commitment of SKCCC Intramural Grant Program funds, yielding $4.98 million in direct costs extramural grants annually, including 13 National Cancer Institute R01s, four other NIH R01s, four U01s, four R21s, two K Awards, one U54 Project and six PPG Projects. The investment also resulted in 152 publications, 14 new clinical trials, and 19 patents. Developmental Funds are requested to continue new investigator recruitment and provide support to staff investigators.
View original record on NIH RePORTER →